Immune checkpoint inhibitors have revolutionized modern oncology by empowering the host immune system to eradicate malignant cells across diverse cancer types. However, this non-specific immune disinhibition frequently triggers immune-related adverse events across various organ systems. While cutaneous, gastrointestinal, and endocrine toxicities occur regularly and are well recognized, neurological adverse events represent an infrequent yet clinically critical category of complications. Because severe neurotoxicity can cause permanent disability or life-threatening impairment, understanding its true incidence is vital for clinical oncologists and multidisciplinary cancer teams. A comprehensive systematic review and meta-analysis of 31 clinical trials involving 8,826 treatment-naive cancer patients provides crucial clarity regarding these complications, offering valuable clinical reassurance and diagnostic guidance for practicing physicians worldwide.

Quantifying the Incidence of Neurological Adverse Events

The systematic review evaluated prospective clinical trials investigating immune checkpoint inhibitors as monotherapy or dual systemic regimens in previously untreated cancer patients. To eliminate confounding toxicities, researchers strictly excluded trials combining immunotherapy with traditional chemotherapy or targeted agents, as well as trials involving heavily pretreated cohorts. The pooled analysis revealed an overall neurological adverse event incidence of 1.78 × 10^-2%, which translates to approximately 1 in 5,000 treated patients (95% confidence interval: 1.06 × 10^-2% to 2.78 × 10^-2%).

This exceptionally low rate provides essential perspective against retrospective pharmacovigilance reports, which frequently overstate neurotoxic risk due to selective reporting of severe or atypical cases. Consequently, clinicians can initiate checkpoint inhibitor regimens with confidence regarding their general neurological safety profile. Nevertheless, because neurological toxicities can escalate rapidly, establishing baseline neurological function before initiating therapy remains standard practice. Furthermore, prompt identification of subtle early symptoms ensures timely intervention before severe neural damage occurs. Routine clinical questioning regarding sensory changes, balance difficulties, or weakness during regular oncology visits supports safe drug delivery and preserves patient quality of life.

Peripheral and Central Nervous System Manifestations

Neurological adverse events secondary to immune checkpoint inhibitors affect both the peripheral and central nervous systems, manifesting across a broad clinical spectrum. In this meta-analysis, peripheral neuropathy represented the most prevalent toxicity, exhibiting a pooled incidence of 1.34 × 10^-2%. Patients typically develop symmetric distal sensory changes, paresthesias, numbness, or mild motor weakness. Furthermore, inflammatory myositis occurred in 0.78 × 10^-2% of patients, characteristically presenting with proximal limb weakness, elevated serum creatine kinase levels, and muscle tenderness.

Central nervous system involvement and neuromuscular junction disorders presented less frequently but carried significant clinical severity. Aseptic meningitis accounted for 0.71 × 10^-2% of cases, requiring immediate lumbar puncture to rule out intracranial infections or leptomeningeal metastasis. Moreover, autoimmune demyelinating polyneuropathy, new-onset epilepsy, and myasthenia gravis each occurred at an incidence of 0.66 × 10^-2%. Checkpoint inhibitor-associated myasthenia gravis often exhibits an aggressive course with rapid diaphragmatic weakness, bulbar involvement, and concurrent myocarditis. Therefore, physicians must maintain an elevated index of suspicion for neuromuscular weakness to initiate life-saving interventions before respiratory failure ensues.

Comparative Safety: Monotherapy Versus Combination Regimens

A critical consideration in modern immuno-oncology is whether combining multiple checkpoint inhibitors magnifies neurotoxic risks compared to single-agent regimens. Dual therapy combining anti-PD-1 or anti-PD-L1 agents with anti-CTLA-4 antibodies enhances antitumor efficacy across refractory malignancies but typically increases overall immune-related toxicity rates. Interestingly, this meta-analysis demonstrated no statistically significant difference in neurological adverse event incidence between monotherapy and dual checkpoint inhibitor regimens (p = 0.481).

Specifically, clinical trials utilizing a single checkpoint inhibitor reported a pooled neurotoxicity incidence of 1.83 × 10^-2%, whereas trials employing two checkpoint inhibitors showed an incidence of 0.90 × 10^-2%. These findings indicate that dual checkpoint blockade does not produce an additive or synergistic neurotoxic effect in clinical trial populations. Therefore, oncologists can select combination regimens based on oncologic efficacy without fear of disproportionate neurological harm, provided they maintain standard surveillance protocols. Nevertheless, multidisciplinary monitoring remains essential, as multisystem inflammatory reactions may still emerge concurrently and complicate overall management.

Cancer Types and Risk Profiles in Clinical Trials

The meta-analysis also conducted detailed subgroup evaluations across distinct tumor types, including non-small cell lung carcinoma, hepatocellular carcinoma, and cutaneous melanoma. Statistical comparison demonstrated no significant difference in the incidence of neurological complications among these primary malignancies (p = 0.622).

Specifically, patients with non-small cell lung carcinoma experienced an adverse event incidence of 1.83 × 10^-2%, while those with hepatocellular carcinoma and melanoma exhibited rates of 1.20 × 10^-2% and 1.16 × 10^-2%, respectively. These uniform findings suggest that systemic host immune activation, rather than specific tumor histology or local microenvironmental factors, drives neurotoxicity. Consequently, clinical vigilance must remain uniform across all cancer indications. Whether managing solid tumors in thoracic, gastrointestinal, or dermatologic oncology, clinicians should apply identical screening and safety monitoring protocols. Standardizing neurotoxicity vigilance across tumor specialties ensures equitable patient care and timely clinical intervention regardless of the primary oncologic diagnosis.

Clinical Vigilance, Diagnostic Workup, and Management

Although neurological complications are uncommon, their potential severity requires structured, rapid diagnostic algorithms. When a patient receiving immunotherapy presents with new headache, altered mental status, visual changes, or motor deficits, clinicians must act rapidly. Workup requires urgent neuroimaging with magnetic resonance imaging, detailed cerebrospinal fluid examination, and serological testing for anti-neuronal antibodies, acetylcholine receptor antibodies, and muscle enzymes to rule out infectious causes or cancer progression.

Management strictly aligns with international oncology guidelines from major professional societies. For mild, Grade 1 sensory symptoms, clinicians may continue immunotherapy under careful observation and supportive care. However, for moderate to severe toxicities (Grade 2 or higher), physicians must promptly withhold the checkpoint inhibitor and initiate systemic corticosteroids, such as oral prednisone or intravenous methylprednisolone. Severe presentations, including myasthenia gravis exacerbations, encephalitis, or acute demyelinating polyneuropathies, warrant immediate hospital admission and escalation to intravenous immunoglobulin or therapeutic plasma exchange. Early multidisciplinary collaboration between oncologists and neurologists consistently improves functional recovery.

Future Directions and Biomarker Research

While clinical trials confirm a low population-level incidence, individual susceptibility factors require further prospective exploration. Future translational studies must identify predictive biomarkers, including specific HLA alleles, circulating autoantibodies, and pre-existing autoimmune markers that predispose patients to neurotoxicity. Such insights will allow tailored risk stratification and personalized therapy selection before treatment initiation.

Furthermore, researchers are actively exploring targeted second-line immunosuppressive agents, such as interleukin-6 receptor antagonists and calcineurin inhibitors, for steroid-refractory neurological events. These targeted biological therapies help suppress harmful neuro-inflammation without completely abrogating systemic antitumor responses. In routine clinical practice, real-world pharmacovigilance registries will complement trial findings by capturing rare phenotypes and delayed-onset toxicities. Combining rigorous diagnostic vigilance, personalized risk stratification, and rapid multidisciplinary management ensures optimal cancer control while preserving neurological function and patient quality of life.

Frequently Asked Questions

How common are neurological toxicities during immune checkpoint inhibitor therapy?

Neurological toxicities are rare during immune checkpoint inhibitor monotherapy or combination therapy. A comprehensive meta-analysis of over 8,800 clinical trial patients estimated the pooled incidence at approximately 1 in 5,000 patients, demonstrating that severe neurotoxic complications occur far less frequently than skin, gut, or endocrine toxicities.

What are the most frequent neurological adverse events associated with ICIs?

Peripheral neuropathy is the most frequently observed neurological complication in clinical trials. Other notable manifestations include inflammatory myositis, aseptic meningitis, acute autoimmune demyelinating polyneuropathy, new-onset seizures, and myasthenia gravis. Although these complications occur infrequently, they require swift diagnostic confirmation and prompt clinical intervention to prevent long-term disability.

How should clinicians manage suspected ICI-induced neurotoxicity in cancer patients?

Clinicians should promptly perform diagnostic imaging and lumbar puncture to rule out tumor progression or infectious etiologies. For moderate to severe presentations, physicians must withhold the checkpoint inhibitor and initiate high-dose corticosteroids. Severe or steroid-refractory cases warrant immediate escalation to intravenous immunoglobulin or plasma exchange.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Toubasi AA et al. The neurological adverse events of immune check point inhibitors in the treatment of cancer. J Neurol. 2026 Jun 06. doi: 10.1007/s00415-026-13925-8. PMID: 42251157.
2. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126.
3. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv119-iv142.